Holen Sie sich die Stockscreener-App
26.75
0.13%
-0.08
Schlusskurs vom Vortag:
$26.83
Offen:
$26.49
24-Stunden-Volumen:
101.70K
Relative Volume:
0.16
Marktkapitalisierung:
$480.72M
Einnahmen:
$116.88M
Nettoeinkommen (Verlust:
$-25.09M
KGV:
-191.07
EPS:
-0.14
Netto-Cashflow:
$-20.74M
1W Leistung:
-9.17%
1M Leistung:
-29.41%
6M Leistung:
+55.69%
1J Leistung:
+77.21%
1-Tages-Spanne:
$26.38
$27.20
1-Wochen-Bereich:
$26.38
$30.60
52-Wochen-Spanne:
$13.57
$43.72
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Firmenname
Rigel Pharmaceuticals
Sektor
Branche
Telefon
650-624-1100
Adresse
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Vergleichen Sie RIGL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
26.80 | 481.26M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
411.61 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
475.60 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.33 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.88 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.43 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-04-03 | Fortgesetzt | Piper Sandler | Neutral |
| 2022-06-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-08 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | Eingeleitet | B. Riley Securities | Neutral |
| 2020-11-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-15 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-09-26 | Fortgesetzt | JP Morgan | Overweight |
| 2019-03-01 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-08-27 | Eingeleitet | Citigroup | Buy |
| 2018-05-02 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-12-21 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-11-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-31 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-30 | Bestätigt | Piper Jaffray | Overweight |
| 2016-07-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-06-13 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2013-04-08 | Bestätigt | Stifel | Buy |
| 2012-11-29 | Eingeleitet | UBS | Neutral |
| 2012-11-06 | Bestätigt | Oppenheimer | Outperform |
| 2012-03-26 | Eingeleitet | Canaccord Genuity | Hold |
| 2010-12-10 | Herabstufung | MP Advisors | Outperform → Market Perform |
Alle ansehen
Rigel Pharmaceuticals Aktie (RIGL) Neueste Nachrichten
After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Rigel (RIGL) - Yahoo Finance
Is Rigel Pharmaceuticals Inc. stock a contrarian buyTrade Analysis Summary & Safe Capital Growth Trade Ideas - newser.com
Can Rigel Pharmaceuticals Inc. (RI2) stock double in coming years2025 Retail Activity & High Accuracy Trade Signal Alerts - newser.com
Rigel Pharmaceuticals Inc. stock volume spike explainedAnalyst Downgrade & Reliable Price Action Trade Plans - newser.com
Can Rigel Pharmaceuticals Inc. stock deliver strong Q4 earningsLong Setup & Daily Volume Surge Trade Alerts - newser.com
Is this a good reentry point in Rigel Pharmaceuticals Inc.Market Risk Summary & Daily Entry Point Trade Alerts - newser.com
Momentum divergence signals in Rigel Pharmaceuticals Inc. chartBreakout Watch & Risk Adjusted Swing Trade Ideas - newser.com
What the charts say about Rigel Pharmaceuticals Inc. todayWeekly Investment Summary & Low Risk High Reward Trade Ideas - newser.com
Why Rigel Pharmaceuticals Inc. stock could see breakout soonRisk Management & Daily Profit Focused Screening - newser.com
Is Rigel Pharmaceuticals Inc. stock recession proofWatch List & Weekly Breakout Stock Alerts - newser.com
How Rigel Pharmaceuticals’ R289 Trial Progress and FDA Designations Will Impact RIGL Investors - Yahoo Finance
Rigel Pharmaceuticals (RIGL): Assessing Valuation Following Key Clinical Milestone for R289 - simplywall.st
Did Rigel's (RIGL) R289 Phase 1b Expansion Just Shift the Company's Pipeline Prospects? - simplywall.st
Is Rigel Pharmaceuticals Inc. stock reversal real or fakeMarket Trend Report & Safe Capital Growth Tips - newser.com
Rigel Pharmaceuticals (NASDAQ:RIGL) Receives "Hold (C+)" Rating from Weiss Ratings - MarketBeat
Rigel Pharmaceuticals stock advances as first patient enrolled in R289 study expansion - Investing.com
Multi factor analysis applied to Rigel Pharmaceuticals Inc.2025 Volume Leaders & Reliable Entry Point Alerts - newser.com
Published on: 2025-10-09 05:05:12 - newser.com
HC Wainwright & Co. Reiterates Rigel Pharmaceuticals (RIGL) Buy Recommendation - Nasdaq
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57 - 富途牛牛
Rigel Pharmaceuticals (NASDAQ:RIGL) Stock Price Down 4%What's Next? - MarketBeat
Rigel Pharmaceuticals (RIGL) Rating Reiterated as 'Buy' by HC Wa - GuruFocus
Rigel Pharmaceuticals' (RIGL) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Rigel Pharmaceuticals, Inc. Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS - MarketScreener
Rigel Pharmaceuticals (RIGL) Advances Phase 1b Study with New Pa - GuruFocus
Rigel announces first patient enrolled in dose expansion phase of 1b study of R289 in patients with lower-risk MDS - MarketScreener
Rigel Pharmaceuticals (NASDAQ:RIGL) Downgraded to "Hold" Rating by Zacks Research - MarketBeat
First patient enrolled: Rigel advances R289 Phase 1b dose expansion, 500 mg qd/bid, up to 40 pts for RP2D - Stock Titan
Does Rigel Pharmaceuticals Inc. qualify in momentum factor screening2025 Market WrapUp & Fast Momentum Stock Entry Tips - newser.com
Will Rigel Pharmaceuticals Inc. (RI2) stock profit from fiscal stimulusWeekly Profit Report & Expert Approved Momentum Trade Ideas - newser.com
Analyzing Rigel Pharmaceuticals Inc. with multi timeframe chartsWeekly Trend Recap & Free Technical Pattern Based Buy Signals - newser.com
Applying Elliott Wave Theory to Rigel Pharmaceuticals Inc.Fed Meeting & Proven Capital Preservation Methods - newser.com
Using portfolio simulators with Rigel Pharmaceuticals Inc. included2025 Bull vs Bear & High Return Trade Opportunity Guides - newser.com
Volume spikes in Rigel Pharmaceuticals Inc. stock – what they mean2025 Stock Rankings & Expert Curated Trade Setups - newser.com
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Eastern Progress
Immune Thrombocytopenic Purpura (ITP) Pipeline 2025: Pioneering Clinical Developments by 30+ Global Leaders – DelveInsight | Featuring Sanofi, Takeda, Rigel Pharmaceuticals, Bristol-Myers Squibb - Barchart.com
Rigel Pharmaceuticals announces inducement grants - MarketScreener
A Deep Dive Into Rigel Pharmaceuticals (RIGL) Valuation After Voya Investment Management Expands Stake - simplywall.st
Rigel Pharmaceuticals (NASDAQ:RIGL) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
What analysts say about Rigel Pharmaceuticals Inc RI2 stockStock Buyback Updates & Free Rapid Wealth Multiplication - earlytimes.in
Voya Strengthens Position in Rigel Pharmaceuticals, Inc. (RIGL) - Insider Monkey
Finanzdaten der Rigel Pharmaceuticals-Aktie (RIGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.30%
0.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):